Nivolumab in resected and unresectable metastatic melanoma: Characteristics of immune-related adverse events and association with outcomes

Clinical Cancer Research

Volumn 22, Issue 4, 2016, Pages 886-894

  Freeman Keller, Morganna ^a   Kim, Youngchul ^a   Cronin, Heather ^a   Richards, Allison ^a   Gibney, Geoffrey ^b   Weber, Jeffrey S ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; NIVOLUMAB; PEPTIDE VACCINE; TRIACYLGLYCEROL LIPASE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ARTICLE; CANCER SURGERY; COLITIS; CYTOTOXIC T LYMPHOCYTE; DIARRHEA; ENDOCRINE DISEASE; ENTERITIS; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTHYROIDISM; HYPOPHYSITIS; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; METASTATIC MELANOMA; MUCOSA INFLAMMATION; MYALGIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RASH; REMISSION; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME; TUMOR REGRESSION; VITILIGO; CHEMICALLY INDUCED; CLINICAL TRIAL; IMMUNOLOGY; KAPLAN MEIER METHOD; MELANOMA; MORTALITY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; SKIN NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; EXANTHEMA; HUMANS; HYPOTHYROIDISM; KAPLAN-MEIER ESTIMATE; MELANOMA; MUCOSITIS; MULTIVARIATE ANALYSIS; PNEUMONIA; PROPORTIONAL HAZARDS MODELS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84964290544     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1136     Document Type: Article

References (49)

1. Lesokhin AM, Callahan MK, Postow MA, Wolchok JD. On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Sci Transl Med 2015;7: 280sr1.
2. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: Impact on clinical outcome. Nat Rev Cancer 2012;12: 298-306.
3. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survivalwith ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
4. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
5. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Antiprogrammed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a Phase 1 trial. Lancet 2014;384:1109-17.
6. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in Advanced Melanoma. N Engl J Med 2015;372:2521-32.
7. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, Phase 3 trial. Lancet Oncol 2015;16: 375-84.
8. Long GV, Atkinson V, Ascierto PA, Brady B, Dutriaux C, Maio M, et al. Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma. J Transl Med 2015;13:2063.
9. Weber JS,Kahler KC,Hauschild A. Management ofimmune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30: 2691-7.
10. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC,McDermottDF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
11. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (Anti-PD-1) in melanoma. NEngl J Med 2013;369:134-44.
12. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33.
13. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015;372:2006-17.
14. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167-75.
15. Ku G, Yuan J, Page D, Schroeder S, Panageas K, Carvajal R, et al. Singleinstitution experience with ipilimumab in advancedmelanoma patients in the compassionate use setting. Cancer 2010;116:1767-75.
16. Sznol M, Kluger HM, Hodi FS, McDermott DF, Carvajal RD, Lawrence DP, et al. Survival and long-term follow-up of safety and response in patients with advanced melanoma in a Phase I trial of nivolumab (anti-PD-1; NIVOLUMAB; ONO-4538). J Clin Oncol 2013;31:abstract CRA9006.
17. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020-30.
18. Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or-naive melanoma. J Clin Oncol 2013;31: 4311-8.
19. Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007;13:6681-8.
20. Madorsky-Rowdo FP, Bar-on A, Urrutia M, Mordoh J. Immunotherapy in cancer: A combat between the tumor and the immune system; you win some, you lose some. Front Immunol 2015;6:127.
21. Daud AI, Hamid O, Ribas A, Hodi FS, Hwu WJ, Kefford R, et al. Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma: Correlation of tumor PD-L1 expression with outcome. In: Proceedings of the American Association for Cancer Research 2014 Annual Meeting; 2014 April 5-9; San Diego, CA: AACR. Abstract nr CT104.
22. Grosso J, Horak CE, Inzunza D, Cardona DM, Simon JS, Gupta AK, et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients with advanced solid tumors treated with nivolumab (anti-PD-1; NIVOLUMAB; ONO-4538). J Clin Oncol 2013;31:abstract CRA3016.
23. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-71.
24. Ascierto PA, Kalos M, Schaer DA, Callahan MK, Wolchok JD. Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res 2013;19:1009-20.
25. A phase I trial of a vaccine combining multiple class I peptides and montanide ISA 51VG with escalating doses of anti-PD-1 antibody nivolumab or ipilimumab with nivolumab for patients with resected stages IIIC/IV melanoma. ClinicalTrials.gov Identifier: NCT01176474.
26. Multiple class I peptides &montanide ISA 51 VGwescalating doses of anti-PD-1 ab BMS936558. ClinicalTrials.gov Identifier: NCT01176461
27. Gibney G, Kudchadkar R, DeConti R, Thebeau M, Czupryn M, Tetteh L, et al. Safety, correlativemarkers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res 2015;21:712-20.
28. Weber J, Antonia S, Topalian S, Schadendorf D, Larkin J, Sznol M, et al. Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis. J Clin Oncol 2015;33:abstract 9018.
29. Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2015;33: 2004-12.
30. McDermott DF, Drake CG, Sznol M, Choueiri TK, Powderly JD, Smith DC, et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol 2015;33:2013-20
31. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, GutierrezM, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015;372:311-9.
32. Johnson DB, Peng C, Sosman JA. Nivolumab in melanoma: Latest evidence and clinical potential. Therap Adv Med Oncol 2015;7:97-106.
33. Ascierto PA. Combination approaches and anti-PD1 therapies: The focus of new research at ESMO and SMR. Melanoma Manage 2015;2:9-14.
34. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34.
35. Amarnath S, Costanzo CM, Mariotti J, Ullman JL, Telford WG, Kapoor V, et al. Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1. PLoS Biol 2010;8:e1000302.
36. Fujiwara H, Maeda Y, Kobayashi K,NishimoriH,Matsuoka K, Fujii N, et al. Programmed death-1 pathway in host tissues ameliorates Th17/Th1-mediated experimental chronic graft-versus-host disease. J Immunol 2014;193:2565-73.
37. Le Poole IC, Wankowicz-Kalinska A, Van Den Wijngaard RM, Nickoloff BJ, Das PK. Autoimmune aspects of depigmentation in vitiligo. J Investig Dermatol Symp Proc 2004;9:68-72.
38. Huang SK, Okamoto T, Morton DL, Hoon DSB. Antibody responses to melanoma/melanocyte autoantigens in melanoma patients. J Invest Dermatol 1998;111:662-7.
39. Cohen JN, Guidi CJ, Tewalt EF. Lymph node-resident lymphatic endothelial cells mediate peripheral tolerance via Aire-independent direct antigen presentation. J Exp Med 2010;207:681-8.
40. Okamoto T, Irie RF, Fujii S, Huang SK, Nizze AJ, Morton DL, et al. Antityrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy. J Invest Dermatol 1998;111:1034-9.
41. Byrne KT, Cot-e AL, Zhang P, Steinberg SM, Guo Y, Allie R, et al. Autoimmune melanocyte destruction is required for robust CD8 memory T cell responses to mouse melanoma. J Clin Invest 2011;121:1797.
42. Fujii S, Huang S, Fong TC, Ando D, Burrows F, Jolly DJ, et al. DSB induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon-retroviral vector inmelanoma patients. Cancer Gene Ther 2000;7:1220-30.
43. Boasberg PD, Hoon DS, Piro LD, Martin MA, Fujimoto A, Kristedja TS, et al. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol 2006;126:2658-63.
44. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006;354:709-18.
45. Bouwhuis MG, Suciu S, Collette S, Aamdal S, Kruit WH, Bastholt L, et al. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. J Natl Cancer Inst 2009;101: 869-77.
46. Tarhini AA, Shin D, Lee SJ, Stuckert J, Sander CA, Kirkwood JM. Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa. Melanoma Res 2014;24:150.
47. Bryce J, Boers-Doets CB. Non-rash dermatologic adverse events related to targeted therapies. Semin Oncol Nurs 2014;30:155-68.
48. Tewalt EF, Cohen JN, Rouhani SJ, Guidi CJ, Qiao H, Fahl SP. Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells. Blood 2014;120: 4772-82.
49. Teulings HE, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB, Spuls PI, et al. Vitiligo-like depigmentation in patients with Stage III-IV melanoma receiving immunotherapy and its association with survival: A systematic review and meta-analysis. J Clin Oncol 2015;33:773-81.